Research shows CGM use can help reduce the risk of serious complications, including diabetic ketoacidosis (DKA), severe low blood sugar events, diabetes-related coma, and hospitalizations for hypoglycemia and hyperglycemia
For detailed information on the subject of data privacy, please refer to our privacy policy listed below
GLP-1R activation leads to the inhibition of inflammation and apoptosis through downstream pathways including the PKA, PKC, and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathways (156, 157)
If GLP-1R agonists are to be used in the treatment of glaucoma patients, their retinopathy status must be determined before start of treatment
Contact your healthcare provider if you notice these symptoms